Promethazine Hydrochloride (Phenergan) Should Not Be Given To Children Under 6: TGA

Australia: The oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be given to children under 6 years of age.

The pharmaceutical company Sanofi-Aventis Healthcare requested the latest updates to advice in the Product Information (PI), Consumer Medicine Information (CMI) and product label for Phenergan, following an internal investigation. This was prompted by a TGA investigation and advice from our Advisory Committee on Medicines.

The PI and CMI documents have been updated to include the risks of psychiatric and central nervous system side effects in children under 6, including hyperactivity, aggression and hallucination. When high doses are given, these children may also experience difficulties in learning and understanding, such as reversible cognitive deficit and intellectual disability.

Phenergan is used to treat a range of conditions including allergies, hayfever and nausea, as well as for short-term sedation.

There are almost 50 other brands of oral promethazine hydrochloride on the Australian market and these sponsors will also be required to update their PI and CMI documents, and product labelling.

Oral promethazine products are currently available as S3 products which can be given to patients over-the-counter on advice from pharmacists.

For more information see Medicines Safety Update: Promethazine hydrochloride (Phenergan) not to be used in children under 6.

Related Posts

  • Pharma
  • February 4, 2025
  • 41 views
Sun Pharma appoints Aalok Shanghvi as Chief Operating Officer

Sun Pharmaceutical Industries has appointed Aalok Shanghvi as its Chief Operating Officer (COO). The company announced the designation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.…

  • Pharma
  • February 4, 2025
  • 47 views
Alembic Pharma Q3 results: PAT falls 23.29% amid market headwinds

Alembic Pharma on Monday reported a 23.29 per cent year-on-year (Y-o-Y) decline in its consolidated profit after tax (PAT) for the third quarter of financial year 2024-25 (Q3FY25) at Rs…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Sun Pharma appoints Aalok Shanghvi as Chief Operating Officer

Sun Pharma appoints Aalok Shanghvi as Chief Operating Officer

Alembic Pharma Q3 results: PAT falls 23.29% amid market headwinds

Alembic Pharma Q3 results: PAT falls 23.29% amid market headwinds

Cipla To Invest Rs 415 Crore In South African Arm To Improve Capital Structure

Cipla To Invest Rs 415 Crore In South African Arm To Improve Capital Structure

Smuggler Apprehended With 62,000 Narcotic Capsules And 6,600 Tablets Valued At 1.5 Million In Saharanpur

Smuggler Apprehended With 62,000 Narcotic Capsules And 6,600 Tablets Valued At 1.5 Million In Saharanpur